Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes

The proprotein convertase subtilisin/kexin type 9 (PCSK9) acts via a canonical pathway to regulate circulating low-density lipoprotein-cholesterol (LDL-C) via degradation of the LDL receptor (LDLR) on the liver cell surface. Published research has shown that PCSK9 is involved in atherosclerosis via...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Ying, Li, Sheng-Lan, Hu, Jia-Hui, Sun, Kai-Jun, Liu, Lei-Ling, Xu, Dan-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071562/
https://www.ncbi.nlm.nih.gov/pubmed/32169071
http://dx.doi.org/10.1186/s12933-020-01009-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071562/
https://www.ncbi.nlm.nih.gov/pubmed/32169071
http://dx.doi.org/10.1186/s12933-020-01009-4

Ejemplares similares